...
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Safety and Efficacy of Reperfusion Therapies for Acute Ischemic Stroke Patients with Active Malignancy
【24h】

Safety and Efficacy of Reperfusion Therapies for Acute Ischemic Stroke Patients with Active Malignancy

机译:急性缺血性脑卒中患者活性恶性肿瘤患者的安全性和有效性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Purpose: Epidemiological correlations between active malignancy (AM) and acute ischemic stroke (AIS) are well-established. However, the effect of reperfusion strategies, particularly mechanical thrombectomy (MT), has been barely investigated in patients with AIS and AM. We aim to evaluate safety and efficacy of reperfusion strategies in such patients. Materials and Methods: We performed a case-control analysis comparing patients with AM and AIS (AM group) to a group of cancer-free patients with AIS (control group). All enrolled patients underwent reperfusion therapies (i.e. intravenous thrombolysis, MT, intravenous thrombolysis plus MT). Main outcomes were 3-month functional independence, successful reperfusion, 3-month mortality, symptomatic intracranial hemorrhage. Results: Total 24 patients with AM and AIS (mean age: 69 +/- 10.1) were individually matched to 24 control patients (mean age: 70.7 +/- 9.3). In both groups 50% were treated with MT, 46% with intravenous thrombolysis and 4% with intravenous thrombolysis plus MT. No difference were found in successful reperfusion, 3-month functional independence, symptomatic intracranial hemorrhage, and mortality. However an overall mortality of 33% in the AM group was reported. Conclusions: Reperfusion strategies for AIS patients with AM seem to be safe and effective. However an individualized approach to understand cancer stage and life-expectation is warranted.
机译:背景和目的:积极恶性肿瘤(AM)和急性缺血性卒中(AIS)之间的流行病学相关性得到良好。然而,再灌注策略,特别是机械血液切除术(MT)的效果几乎没有针对AIS和AM的患者研究。我们的目标是评估再灌注策略在此类患者中的安全性和功效。材料和方法:我们进行了案例对照分析,将患者和AIS(AM组)与AIS(对照组)的无癌症患者进行比较。所有注册的患者都接受了再灌注疗法(即静脉溶栓,MT,静脉溶栓加MT)。主要结果为3个月的功能独立,成功再灌注,3个月死亡率,症状颅内出血。结果:24例AM和AIS(平均年龄:69 +/- 10.1)与24例对照患者单独匹配(平均年龄:70.7 +/- 9.3)。在两组中,50%用MT,46%对静脉溶栓治疗,4%与静脉溶栓加MT。在成功再灌注,3个月的功能独立性,症状性颅内出血和死亡率没有差异。然而,报告了AM组中的33%的总体死亡率。结论:AIS患者的再灌注策略似乎是安全有效的。然而,有必要了解癌症阶段和生命期望的个性化方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号